New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE
A new Phase 3 study published in the New England Journal of Medicine found that Gazyva® (obinutuzumab) significantly reduced disease...
Lupus Research Alliance
